SCHEMBL12662495

SCHEMBL12662495

O=C(Nc1ccccn1)c1cccc2[nH]c(-c3cnccc3C(F)(F)F)nc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 5/20 0.53
▸ PKN1 Q16512 4/20 0.44
▸ PKN2 Q16513 4/20 0.44
▸ CHRNB2 P17787 1/20 0.42
▸ CHRNB4 P30926 1/20 0.42
▸ CHRNA3 P32297 1/20 0.42
▸ CHRNA4 P43681 1/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ GRM5 P41594 1/20 0.41
▸ DHODH Q02127 3/20 0.40
▸ PARP2 Q9UGN5 1/20 0.40
▸ PLK4 O00444 1/20 0.40
▸ MAPK13 O15264 1/20 0.40
▸ DYRK3 O43781 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ RPS6KA5 O75582 1/20 0.40
▸ PRKD3 O94806 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1896561 0.90 PARP1 (0.65) PARP1PKN1PKN2CHRNB2CHRNB4
SCHEMBL12673141 0.86 PARP1 (0.52) PARP1PKN1PKN2CHRNB2CHRNB4
SCHEMBL12662022 0.85 PARP1 (0.51) PARP1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL12673356 0.84 PARP1 (0.52) PARP1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL12662492 0.83 PARP1 (0.48) PARP1PKN1PKN2NPC1RAB9A
SCHEMBL12662386 0.83 PARP1 (0.52) PARP1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL1897596 0.82 PARP1 (0.47) PARP1PKN1PKN2MEN1KMT2A
SCHEMBL1889225 0.82 PARP1 (0.60) PARP1PKN1PKN2KDM4EDHODH
SCHEMBL12662471 0.81 PARP1 (0.46) PARP1MEN1KMT2AGRM5DHODH
SCHEMBL1896489 0.80 PKN1 (0.64) PARP1PKN1PKN2KDM4EDHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2315763-B1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2016-06-01 — — EP disclosed
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2015-02-26 — — US disclosed
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2015-02-26 — — US disclosed
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-05-26 — — US disclosed
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2011-05-26 — — US disclosed
WO-2010003048-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRTRIS PHARMACEUTICALS, INC. (US) 2010-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124637-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 PARP1 287/4885PKN1 1869/4885PKN2 2053/4885
US-20150057272-A1 BENZIMIDAZOLES AND RELATED ANALOGS AS SIRTUIN MODULATORS SIRT3, SIRT1, SIRT2 PARP1 331/4885PKN1 2208/4885PKN2 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback